Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, scheduled for March 3-5, 2025. President and CEO Joe Oliveto will lead a fireside chat presentation on March 4th at 9:10 AM EST.
The presentation will be accessible through a live webcast for conference attendees, with a replay option available for approximately 90 days afterward on the company's website in the News & Events section at www.milestonepharma.com. Interested parties seeking meetings with the Milestone team during the conference should contact their TD Cowen representative.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MIST declined 0.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.
A live webcast of the fireside chat will be available to conference participants on March 4th at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
When is Milestone Pharmaceuticals (MIST) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access Milestone Pharmaceuticals' (MIST) TD Cowen conference presentation?
Who will represent Milestone Pharmaceuticals (MIST) at the 2025 TD Cowen Healthcare Conference?
How long will the replay of MIST's TD Cowen conference presentation be available?
